Related Experiment Video
Updated: Dec 13, 2025

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
Published on: April 28, 2020
Severe COVID-19 patients with liver injury: a seven-case series
1Department of Neurology, The Third Central Clinical College of Tianjin Medical University, Tianjin, China. doctorlixia@tmu.edu.cn.
Insights
Severe COVID-19 can cause liver injury, particularly in elderly patients with underlying conditions. Monitoring liver function is crucial for these vulnerable individuals during infection.
Area of Science:
- Hepatology
- Infectious Diseases
- Critical Care Medicine
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily targets the respiratory system.
- The impact of coronavirus disease 2019 (COVID-19) on liver function, especially in severe cases, requires further investigation.
Observation:
- Seven elderly patients with severe COVID-19 and comorbidities (hypertension, diabetes, coronary heart disease) developed hepatic injury.
- Elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were observed during the second week of illness.
- Liver function normalized within one week with conventional supportive care.
Findings:
- COVID-19 infection can lead to liver injury, evidenced by elevated transaminase levels.
- Potential mechanisms include direct viral effect, immune-mediated damage (cytokine storm syndrome), and hypoxic injury to hepatocytes.
- Hepatic injury in COVID-19 patients is associated with disease severity and patient comorbidities.
Implications:
- Close monitoring of liver function is recommended for elderly COVID-19 patients with comorbidities.
- Understanding COVID-19's hepatotoxicity is vital for comprehensive patient management.
- Further research into the mechanisms of COVID-19-induced liver injury may inform therapeutic strategies.
Abstract:
We present the case details of seven patients diagnosed with severe novel coronavirus disease 2019 (2019-nCoV, hereafter COVID-19) with hepatic injury. Most of these patients were elderly and had hypertension, diabetes mellitus, coronary heart disease, and other underlying health conditions prior to admission for COVID-19. Liver injury occurred in all seven cases during the course of the disease. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels initially increased (1.2-times to 2.0-times the normal value, respectively) in the second week. The liver function recovered in all patients within one week of conventional liver protection treatment. Elevated serum transaminase levels in these patients were due to the COVID-19 infection but could also be related to systemic immune response caused by cytokine storm syndrome (CSS) and hepatocyte damage caused by ischemia and hypoxia. COVID-19 is highly infectious and mainly affects the lungs. In some cases, especially in patients with severe disease type, COVID-19 may also cause liver injury. The liver function of patients with severe COVID-19 should be very carefully monitored, especially if the patients are elderly and have underlying comorbidities.
More Related Videos
Related Concept Videos
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

